LACTEL 50:50 DL-PLG (B6010-1) is an ester-terminated poly(DL-lactide-co-glycolide) supplied as a white to off-white powder for biomedical matrix applications. The catalogue designation B6010-1 identifies the standard-viscosity member of the 50:50 DL-PLG series; the same comonomer ratio is also available with acid end caps and with lower or higher inherent viscosity grades for different release and processing requirements. The 0.55–0.75 dL/g inherent viscosity window of B6010-1 is commonly selected when the formulation requires enough chain length to form coherent microspheres, films, rods, or foamed scaffolds without creating excessively high solution viscosity for sterile filtration of process intermediates. In pharmaceutical development, the material is used as a biodegradable carrier in injectable microspheres, subcutaneous implants, intraocular drug delivery matrices, and tissue-engineering scaffolds produced by solvent casting, electrospinning, or melt processing. Because PLGA degrades by bulk hydrolysis, the polymer must be handled as a moisture-sensitive intermediate; storage below -20 °C in sealed desiccated containers is standard.

What certificate-of-analysis parameters define B6010-1 acceptance?

The release profile of B6010-1 is controlled through the certificate of analysis, which should report the DL-lactide:glycolide ratio, inherent viscosity, end-group functionality, residual monomer, residual solvent, and moisture content. The nominal molar ratio is 50:50 DL-lactide:glycolide, but the accepted batch-specific ratio may be specified as a narrow band around the nominal value; measurement is by proton nuclear magnetic resonance integration. Inherent viscosity is specified at 0.55–0.75 dL/g using a dilute-solution capillary viscometry method aligned with ISO 1628-1:2021 for polymer solution viscosity. The glass transition temperature of dry 50:50 PLGA typically lies between 40 °C and 50 °C by differential scanning calorimetry; the exact value changes with residual solvent and thermal history. Residual moisture is normally determined by Karl Fischer titration, and melt processing should not begin when moisture exceeds 0.2 wt%. Residual solvent limits are not fixed by the polymer grade alone; they must be set against the intended finished-device monograph or ICH Q3C criteria.

The ester terminal group in B6010-1 reduces the initial concentration of free carboxylic acid relative to the acid-capped analogue B6001-1. This difference influences early-stage hydrolysis in aqueous media and can extend the induction period before appreciable molecular weight loss is observed. In emulsion-based microencapsulation, an acid-capped PLGA of the same 50:50 ratio and 0.55–0.75 dL/g viscosity may generate a more acidic polymer phase immediately after solvent evaporation, which can affect acid-labile active pharmaceutical ingredients. B6010-1 does not completely prevent acid generation; once water diffuses into the matrix and cleaves ester bonds, new terminal carboxyl groups are formed and autocatalysis proceeds. The practical benefit is a more neutral starting condition for the organic phase and often a more reproducible early-release phase when the formulation is transferred from laboratory to controlled-environment manufacturing.

Ester-capped versus acid-capped degradation kinetics

Hydrolytic degradation of B6010-1 follows bulk erosion rather than surface erosion because water diffusion into the amorphous polymer phase is rapid compared with ester hydrolysis. At 37 °C, water uptake plasticizes the matrix and lowers the effective glass transition below the incubation temperature, increasing chain mobility. The 50:50 ratio contains enough glycolide to make the polyester amorphous and hydrolytically labile; degradation is faster than 75:25 or 85:15 PLGA because the higher glycolide content increases the density of relatively hydrophilic glycolate ester units. For comparative in vitro degradation tests, protocols often follow ASTM F1635-16 in phosphate-buffered saline at 37 °C; however, the measured molecular weight half-life is not a single-valued property of the polymer because geometry, porosity, and medium exchange rate alter internal acid accumulation. Dense implants can develop a low-pH core and undergo faster internal chain scission than the surface, while thin films and fine microspheres allow acid diffusion and degrade more uniformly.

Compared with semicrystalline poly(L-lactide-co-glycolide) grades, B6010-1 remains amorphous after solvent casting and compression molding because the DL-lactide sequence disrupts stereoregular chain packing. This lowers modulus and strength relative to lactide-rich grades, but it removes crystallinity-driven phase separation and spherulite formation during drying. For lipophilic drugs, the amorphous matrix can reduce crystallization-induced drug exclusion; for hydrophilic drugs, the bulk erosion pattern can create continuous release pathways rather than surface-limited diffusion. The trade-off is a shorter load-bearing window, which makes B6010-1 less suitable for orthopedic fixation devices where 85:15 PLGA or poly(L-lactide) is selected for retaining mechanical strength over several months.

Gel permeation chromatography of B6010-1 samples often shows a unimodal molecular weight distribution with a polydispersity index between 1.5 and 2.0, typical for linear PLGA produced by ring-opening polymerization. A shoulder or broadening at the low molecular weight tail is taken as evidence of hydrolytic or thermal degradation during storage or processing. In manufacturing, incoming-lot GPC overlays are compared at fixed retention time windows; a shift in the main peak below the accepted window can cause faster release and lower microsphere yield. Because the polymer is amorphous, the GPC signal is not confounded by crystalline dissolution issues that can occur with L-lactide-rich PLGA.

Controlling melt viscosity and particle size in B6010-1 processing

For hot-melt extrusion and injection molding, B6010-1 must be dried before heating. Vacuum drying at 25–30 °C for 12–24 h or use of a desiccant dryer with a dew point below -40 °C is common; Karl Fischer titration should confirm moisture below 0.2 wt%. Melt processing temperatures for this viscosity grade are generally restricted to 100–140 °C, and residence time should remain below 5 min. Above 150 °C, thermal chain scission and ester interchange accelerate, causing a measurable reduction in molecular weight and a decrease in melt strength. Twin-screw extruders with L/D ratios between 25:1 and 40:1, vented barrels, and low-shear screw profiles are preferred for drug-polymer blends because they limit stagnant zones and provide controlled temperature uniformity. Injection molding machines used with B6010-1 require low-compression screws and back pressures that avoid excessive shear heating; melt temperature should be monitored at the nozzle rather than inferred from barrel set points.

In solvent-based microsphere and nanoparticle manufacturing, B6010-1 is dissolved in dichloromethane or chloroform at polymer concentrations commonly between 5 wt% and 20 wt%, depending on target particle size and emulsion rheology. Single-emulsion oil-in-water processing is used for poorly water-soluble active pharmaceutical ingredients, while double-emulsion water-oil-water processing is required for water-soluble peptides and proteins. High-shear homogenization or rotor-stator dispersion at 5 000–15 000 rpm is used to form the primary emulsion; the median particle size is then controlled by the shear rate, continuous-phase viscosity, and the ratio of polymer solution to aqueous phase. Solvent extraction with cold water or ethanol reduces hardening time and can produce a denser particle skin, while slow solvent evaporation tends to produce a more porous interior. A batch at the lower end of the 0.55–0.75 dL/g specification may require an increase in polymer concentration or a reduction in homogenizer speed to maintain the same particle size distribution as a batch at the upper end.

Electrospinning of B6010-1 from chlorinated solvents produces nonwoven fibrous mats for soft-tissue scaffolds; solution concentration must be adjusted with conductivity and vapor pressure to avoid bead formation. Salt-leaching and phase-inversion methods produce open-pore constructs, but residual salt or solvent must be reduced to accepted biomedical limits. In all of these routes, the polymer’s inherent viscosity affects the transition from droplet or jet to solid fiber or particle. Tight incoming-lot viscosity control below the 0.55–0.75 dL/g range is therefore more important than exact molecular weight averaging in routine production.

Residual lactide and glycolide monomer in B6010-1 should be verified against the certificate of analysis before use in injectable formulations. Elevated monomer content can plasticize the matrix, reduce glass transition temperature, and increase the initial burst release. Residual chloroform or dichloromethane is controlled by gas chromatography; the applicable limit depends on route of administration and is typically taken from ICH Q3C or pharmacopoeial general chapters. Vacuum drying after microsphere fabrication at 25–30 °C for 12–48 h reduces solvent content, but drying protocols must be balanced against particle aggregation and surface film formation.

When terminal sterilization is required for implantable formats

Terminal sterilization of B6010-1-containing implants and microspheres requires dose-setting studies because gamma irradiation at normal doses can reduce molecular weight and alter release. A reference dose of 25 kGy, applied under ISO 11137-1:2006 with dose setting per ISO 11137-2:2013, may produce chain scission and free-radical oxidation in the polyester. The extent of degradation depends on moisture, oxygen, antioxidant content, and packaging density; dose mapping in loaded containers is necessary to avoid regions of local overdosing. Ethylene oxide sterilization is an alternative but the polymer must be degassed to meet residual ethylene oxide and ethylene chlorohydrin limits under ISO 10993-7:2008. Aseptic processing of the final solid is not feasible for most melt-processed or solvent-cast matrices; filtration of the polymer solution may be used before particle hardening, but terminal sterilization decisions must be integrated with in-process bioburden control.

Storage and handling of B6010-1 after terminal sterilization should preserve the low moisture content achieved during drying. Sealed glass or foil pouches are held at -20 °C; containers are brought to room temperature before opening to prevent condensation. Repeated freeze-thaw cycles increase water adsorption and should be avoided. For finished biomedical devices, the biological safety of the polymer cannot be certified solely by the polymer supplier; the final device must be evaluated under ISO 10993-1:2018, with test selection based on contact duration and tissue type. Cytotoxicity, sensitization, irritation, and implantation tests are commonly required for a subcutaneously implanted microsphere or rod. Residual solvent and monomer levels are part of the finished-product specification, not the raw-polymer CoA alone.